Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials-Reference-Cited by-同舟云学术

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials

Published:2014-02 Issue:2 Volume:83 Page:231-239
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Shi Liang,Tang Junfang,Tong Li,Liu Zhe

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference50 articles.

1. Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the ideal 1 trial) [corrected];Fukuoka;J Clin Oncol,2003

2. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial;Kris;JAMA,2003

3. Fda drug approval summary: erlotinib (tarceva) tablets;Cohen;Oncologist,2005

4. Efficacy of egfr tyrosine kinase inhibitors in patients with egfr-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials;Petrelli;Clin Lung Cancer,2012

5. Severe acute interstitial pneumonia and gefitinib;Inoue;Lancet,2003

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Reactions and Radiation Effects;Pulmonary Pathology;2025

2. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis;Targeted Oncology;2024-06-01

3. Drug-induced Lung Disease in the Oncology Patient;Clinics in Chest Medicine;2024-06

4. Repeat biopsy versus initial biopsy in terms of complication risk factors and clinical outcomes for patients with non-small cell lung cancer: a comparative study of 113 CT-guided needle biopsy of lung lesions;Frontiers in Oncology;2024-05-13

5. Successful rechallenge twice with different EGFR-TKIs in a patient with lung adenocarcinoma after EGFR- TKI-induced grade 3 stomatitis and interstitial lung disease: a case report;2024-04-03